JP2016513730A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513730A5
JP2016513730A5 JP2016502750A JP2016502750A JP2016513730A5 JP 2016513730 A5 JP2016513730 A5 JP 2016513730A5 JP 2016502750 A JP2016502750 A JP 2016502750A JP 2016502750 A JP2016502750 A JP 2016502750A JP 2016513730 A5 JP2016513730 A5 JP 2016513730A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
pharmaceutically acceptable
acceptable salt
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513730A (ja
JP6442475B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/028274 external-priority patent/WO2014144037A1/en
Publication of JP2016513730A publication Critical patent/JP2016513730A/ja
Publication of JP2016513730A5 publication Critical patent/JP2016513730A5/ja
Application granted granted Critical
Publication of JP6442475B2 publication Critical patent/JP6442475B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502750A 2013-03-15 2014-03-14 Ｌｘｒ調節因子 Expired - Fee Related JP6442475B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786974P 2013-03-15 2013-03-15
US61/786,974 2013-03-15
PCT/US2014/028274 WO2014144037A1 (en) 2013-03-15 2014-03-14 Lxr modulators

Publications (3)

Publication Number Publication Date
JP2016513730A JP2016513730A (ja) 2016-05-16
JP2016513730A5 true JP2016513730A5 (enExample) 2017-04-20
JP6442475B2 JP6442475B2 (ja) 2018-12-19

Family

ID=51537598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502750A Expired - Fee Related JP6442475B2 (ja) 2013-03-15 2014-03-14 Ｌｘｒ調節因子

Country Status (5)

Country Link
US (1) US9834542B2 (enExample)
EP (1) EP2968275B1 (enExample)
JP (1) JP6442475B2 (enExample)
CN (1) CN105209039B (enExample)
WO (1) WO2014144037A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
CN104817525B (zh) * 2015-04-13 2017-11-17 江苏大学 含氟2,3‑二氢苯并呋喃‑3‑醇类化合物及制备方法
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
TWI748194B (zh) * 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
CN119431265A (zh) * 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
CN110330493B (zh) * 2019-08-23 2020-07-24 广州麓鹏制药有限公司 Pim激酶抑制剂、其制备方法、应用、药物及药物组合
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用
CN117659069A (zh) * 2023-12-05 2024-03-08 南通敏言生物医药科技有限公司 一种2-甲基-5-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)喹啉的合成方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5874452A (en) 1996-04-03 1999-02-23 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
WO1997036897A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859035A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
JP2000509371A (ja) 1996-04-03 2000-07-25 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
EP1019059A4 (en) 1997-01-24 2004-01-14 Univ California USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE
AU747110B2 (en) 1998-02-25 2002-05-09 Merck & Co., Inc. Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist
AU5994199A (en) 1998-09-23 2000-04-10 Alexander Mata De Urquiza Analysis of ligand activated nuclear receptors (in vivo)
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
EP1190065A2 (en) 1999-06-18 2002-03-27 Cv Therapeutics, Inc. Atp binding cassette transporter protein abc1 polypeptides
AU2001262984A1 (en) 2000-05-03 2001-11-12 Tularik, Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
KR101363278B1 (ko) * 2005-06-27 2014-02-21 엑셀리시스 페이턴트 컴퍼니 엘엘씨 이미다졸계 ｌｘｒ 변조제
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2121621B1 (en) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
MY153958A (en) * 2009-05-28 2015-04-30 Exelixis Patent Co Llc Lxr modulators
TW201242953A (en) * 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators

Similar Documents

Publication Publication Date Title
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
JP2014507455A5 (enExample)
IL227990B (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases
JP2017537066A5 (enExample)
MY187988A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
JP2014506907A5 (enExample)
MY159058A (en) Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
MX359221B (es) Derivados de tienopiridona útiles como activadores de ampk.
JP2014513110A5 (enExample)
JP2016522835A5 (enExample)
WO2012177481A3 (en) Fibroblast growth factor receptor inhibition for the treatment of disease
MX2010014057A (es) Compuestos de piridina.
JP2016510326A5 (enExample)
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
JP2016500063A5 (enExample)
JP2015502951A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2015500223A5 (enExample)
CL2012002621A1 (es) Polimorfo forma i, ii, iii, iv y vi de 4-trifluorometil-n-(3,3a,4,4a,5,5a,6,6a-octahidro-1,3-dioxo-4,6-etenocicloprop[f]isoindol-2(1h)-il)-benzamida (st-246); metodo para producirlas; composicion farmaceutica; forma de dosificacion unitaria; y metodo de tratamiento de infecciones por ortopoxvirus y de eczema vacunal.
JP2016518334A5 (enExample)
JP2013525356A5 (enExample)
WO2014192030A3 (en) An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof
CL2013001390A1 (es) 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato sodico; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o profilaxis de enfermedades tales como insuficiencia cardiaca, anemia, insuficiencia renal y enf. cardiovasculares.
HRP20192275T1 (hr) Novi spojevi 3,4-dihidro-2h-izokinolin-1-ona i 2,3-dihidro-izoindol-1-ona